No dose-limiting toxicities, severe adverse events, or on-target off-tumor toxicities across all dose cohorts Deep and durable response observed in gastroesophageal cancer EXUMA now advancing its clinically de-risked solid tumor & hematologic CARs with in vivo GCAR™ platform and SCL mRNA…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.